Ge healthcare announces fda approval of pediatric indication for optison ultrasound enhancing agent

Arlington heights, ill.--(business wire)--ge healthcare (nasdaq: gehc) today announced the u.s. food and drug administration (fda) has approved a pediatric indication for the company's optison™ (perflutren protein-type a microspheres injectable suspension, usp) ultrasound enhancing agent (uea). this approval will help improve the clarity and diagnostic accuracy of echocardiograms in pediatric patients, giving cardiologists a fuller picture of ventricular function when assessing possible heart a.
GEHC Ratings Summary
GEHC Quant Ranking